STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES. STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).
Stocks highlighted in this watchlist include: $IMMU, $CORI, $EKSO
IMMU: Float of 116.14 million shares with 19.91% short.
The Company announced on November 16, 2017, the completion of the enrollment in the first of its two registrational Phase-3 clinical trials, Study BHV3000-301, to establish the safety and efficacy of orally-dosed rimegepant for the acute treatment of migraine.
Also significant progress made toward preparing a BLA for accelerated approval of IMMU-132, the breakthrough therapy candidate for the treatment of late-stage metastatic triple-negative breast cancer (mTNBC). IMMU-132 has shown a remarkable response rate in patients.
Immunomedics also announced that its Board of Directors has voted to appoint Michael Pehl as President and Chief Executive Officer (“CEO”), effective December 7, 2017.
Tthe abstract on updated results from the Phase 2 study of IMMU-132 in patients with mTNBC was accepted for an oral presentation at the 2017 San Antonio Breast Cancer symposium (SABCS) on December 5-9, 2017. A second abstract on the Phase 3 ASCENT trial design has also been accepted for poster presentation at the same SABCS conference.
CORI: Float of 33.43 million shares with 5.24% short. Biopharma company Corium International Inc reported 19% revenue growth for Q4 2017 while its loss per share narrowed to 36 cents from 42 cents. The company also detailed a slew of upcoming catalysts, including a Dec. 26 PDUFA action date for its partner Agile Therapeutics Inc (NASDAQ: AGRX)'s Twirla, a once-weekly contraceptive.
HC Wainwright analyst Oren Livnat reviewed the results in a Thursday note. The analyst reiterated a Buy rating and a $15 price target. Corium reported above-consensus results ahead of near-term catalysts, Livnat said in a note. The analyst delved on a slew of near-term catalysts that could support the stock, which included:
The PDUFA date for Agile's Twirla contraceptive patch, which could fetch Corium peak of revenue of $50 million per year;
Çommercial partnership for Corium's lead asset donepezil weekly patch for Alzheimer's either this year or in the first half of 2018, with the analyst estimating peak revenues of $200 million for Corium; and
Update from FDA on whether the positive pilot donepezil patch bioequivalence study would be considered as pivotal study for a NDA filing.
EKSO: Float of 23.04 million shares with 10.06% short. This stock was on my November 13th watchlist at 1.53. It's currently at $4.13 for a 270% gain already with more to come.
The deal that send EKSO soaring was in providing Ford with exoskeletons for their workers to use. These exoskeletons are for the upper half of the body and provide support to employees that have to handle overhead work during vehicle assembly.
The exoskeleton from Ekso Bionics Holdings, Inc. that offers this support is the EksoVest. The purpose of this vest is to reduce the amount of fatigue and strain that Ford employees experience when doing overhead work. It will also hopefully reduce injuries as well.